Merigolix

Last updated

Merigolix
Merigolix.svg
Clinical data
Other namesHS-10518; NCE-403; SKI-2670; TU-2670
Routes of
administration 		Oral [1]
Drug class GnRH antagonist
Identifiers
  • 4-[[(1R)-2-[1-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-2,4-dioxo-1'-[[5-(trifluoromethyl)furan-2-yl]methyl]spiro[7H-furo[3,4-d]pyrimidine-5,4'-piperidine]-3-yl]-1-phenylethyl]amino]butanoic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C36H35F7N4O6
Molar mass 752.687 g·mol−1
3D model (JSmol)
  • C1CN(CCC12C3=C(CO2)N(C(=O)N(C3=O)C[C@@H](C4=CC=CC=C4)NCCCC(=O)O)CC5=C(C=CC=C5F)C(F)(F)F)CC6=CC=C(O6)C(F)(F)F
  • InChI=1S/C36H35F7N4O6/c37-26-9-4-8-25(35(38,39)40)24(26)19-46-28-21-52-34(13-16-45(17-14-34)18-23-11-12-29(53-23)36(41,42)43)31(28)32(50)47(33(46)51)20-27(22-6-2-1-3-7-22)44-15-5-10-30(48)49/h1-4,6-9,11-12,27,44H,5,10,13-21H2,(H,48,49)/t27-/m0/s1
  • Key:LJPSGSMPGVITHK-MHZLTWQESA-N

Merigolix (INN Tooltip International Nonproprietary Name; developmental code names HS-10518, NCE-403, SKI-2670, TU-2670) is a gonadotropin releasing hormone (GnRH) antagonist which is under development for the treatment of endometriosis and uterine fibroids. [1] [2] [3] [4] [5] It is taken by mouth. [1] The drug is being developed by TiumBio, Daewon Pharmaceutical, and Jiangsu Hansoh Pharmaceutical. [1] [2] As of October 2024, it is in phase 2 clinical trials for both endometriosis and uterine fibroids. [1] [2]

See also

References

  1. 1 2 3 4 5 "Merigolix". AdisInsight. 28 October 2024. Retrieved 24 February 2025.
  2. 1 2 3 "Delving into the Latest Updates on Merigolix with Synapse". Synapse. 22 February 2025. Retrieved 24 February 2025.
  3. ↑ Tukun FL, Olberg DE, Riss PJ, Haraldsen I, Kaass A, Klaveness J (December 2017). "Recent Development of Non-Peptide GnRH Antagonists". Molecules. 22 (12): 2188. doi: 10.3390/molecules22122188 . PMC   6149776 . PMID   29232843.
  4. ↑ Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G (2019). "Uterine fibroids: an update on current and emerging medical treatment options". Therapeutics and Clinical Risk Management. 15: 157–178. doi: 10.2147/TCRM.S147318 . PMC   6350833 . PMID   30774352.
  5. ↑ Angioni S, D'Alterio MN, Daniilidis A (2021). "Highlights on Medical Treatment of Uterine Fibroids". Current Pharmaceutical Design. 27 (36): 3821–3832. doi:10.2174/1381612826666210101152820. PMID   33388011.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.